Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Tvardi Therapeutics, Inc. (TVRD) P/E ratio
Tvardi Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 240× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | (100.00%) |
| FY2020 | 168× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| DYAI Dyadic International Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| GUTS Fractyl Health, Inc. compare | n/m |
| TVRD Tvardi Therapeutics, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 21.7× |
| Market median | 16.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)